Lista de obras - Koichi Takahashi - Dominio Público Uruguay

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

artículo científico publicado en 2018

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

artículo científico publicado en 2018

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2016

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia

scientific article published on 23 July 2013

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

artículo científico publicado en 2015

Cancer therapy shapes the fitness landscape of clonal hematopoiesis

artículo científico publicado en 2020

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

artículo científico publicado en 2017

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

artículo científico publicado en 2014

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

artículo científico publicado en 2015

Chromosome 5q deletion is extremely rare in patients with myelofibrosis

artículo científico publicado en 2013

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

artículo científico publicado en 2017

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

artículo científico publicado en 2020

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

scientific article published on 29 October 2020

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

scientific article published on 29 July 2013

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

artículo científico publicado en 2016

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

artículo científico publicado en 2018

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

artículo científico publicado en 2015

Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations

scientific article published on 17 August 2020

Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission

artículo científico publicado en 2015

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

artículo científico publicado en 2020

Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

artículo científico publicado en 2019

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

artículo científico publicado en 2015

Copy number alterations detected as clonal hematopoiesis of indeterminate potential

scientific article published on 19 June 2017

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

artículo científico publicado en 2015

Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion

artículo científico publicado en 2015

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

artículo científico publicado en 2018

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

scientific article published on 01 May 2019

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis

artículo científico publicado en 2016

Hematologic malignancies and Li-Fraumeni syndrome

artículo científico publicado en 2019

High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics

article by Maurizio Pellegrino et al published September 2018 in Genome Research

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

artículo científico publicado en 2018

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2019

Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels

scientific article published on 06 April 2018

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia

artículo científico publicado en 2022

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

artículo científico publicado en 2018

JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms

artículo científico publicado en 2013

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

scholarly article by Musa Yilmaz et al published 16 January 2019 in Blood Cancer Journal

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

artículo científico publicado en 2021

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia

scientific article published on 25 September 2019

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

artículo científico publicado en 2017

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia

artículo científico publicado en 2019

Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3)

artículo científico publicado en 2020

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

artículo científico publicado en 2017

Nuclear NAD<sup>+</sup> homeostasis governed by NMNAT1 prevents apoptosis of acute myeloid leukemia stem cells

artículo científico publicado en 2021

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

artículo científico publicado en 2016

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

scientific article published on 28 February 2020

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

artículo científico publicado en 2018

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

scientific article published on 20 December 2018

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

artículo científico publicado en 2020

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2017

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

artículo científico

Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

artículo científico publicado en 2020

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

artículo científico publicado en 2017

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

artículo científico publicado en 2017

Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD

artículo científico publicado en 2013

Statistical tests for intra-tumour clonal co-occurrence and exclusivity

artículo científico publicado en 2021

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

artículo científico publicado en 2022

T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid

artículo científico publicado en 2020

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens

artículo científico publicado en 2017

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

artículo científico publicado en 2016

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival

scientific article published on 19 November 2019

Ups and downs of CHIP

artículo científico publicado en 2018

Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

scientific article published on 02 December 2020

Lista de obras de Koichi Takahashi

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Cancer therapy shapes the fitness landscape of clonal hematopoiesis

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

Chromosome 5q deletion is extremely rare in patients with myelofibrosis

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations

Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

Copy number alterations detected as clonal hematopoiesis of indeterminate potential

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis

Hematologic malignancies and Li-Fraumeni syndrome

High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia

Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3)

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

Nuclear NAD<sup>+</sup> homeostasis governed by NMNAT1 prevents apoptosis of acute myeloid leukemia stem cells

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD

Statistical tests for intra-tumour clonal co-occurrence and exclusivity

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival

Ups and downs of CHIP

Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy